Medline Inc. (MDLN) KPIs and segments
Close on Nov 18, 2026Market cap $51.48BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Medline · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Medline: 38 chỉ số vận hành, trong đó có Prime Vendor Net Sales, Total New Customer Signings và Organic Net Sales Growth, lấy từ 27 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supply Chain Solutions($M) | 4,145 | 3,887 | 3,564 | 3,380 | |||||||||
Medline Brand($M) | 3,540 | 3,465 | 3,322 | 3,264 | |||||||||
Acute care($M) | 5,407 | 5,125 | 4,716 | 4,572 | |||||||||
Non-Acute care($M) | 1,745 | 1,732 | 1,683 | 1,622 | |||||||||
Front Line Care($M) | 1,652 | 1,618 | 1,592 | 1,526 | |||||||||
Surgical Solutions($M) | 1,640 | 1,554 | 1,509 | 1,447 | |||||||||
Laboratory and Diagnostics($M) | 248 | 293 | 221 | 291 | |||||||||
United States($M) | 7,152 | 6,857 | 6,399 | 6,194 | |||||||||
International($M) | 533 | 495 | 487 | 450 | |||||||||
Medline Brand($M) | 1,067 | 765 | 890 | 830 | |||||||||
Supply Chain Solutions($M) | 204 | 187 | 201 | 182 | |||||||||
Prime Vendor Net Sales($M)3 | 5,285 | 5,226 | 4,913 | 4,914 | 4,441 | 4,418 | 4,260 | 4,325 | |||||
Prime Vendor Net Sales Growth (YoY)(%) | 19.0% | 18.3% | 15.3% | ||||||||||
Prime Vendor — Supply Chain Solutions Net Sales($M)1 | 3,566 | 3,519 | 3,308 | 3,307 | 2,993 | 2,942 | 2,807 | 2,832 | |||||
Prime Vendor — Supply Chain Solutions Growth (YoY)(%) | 19.1% | 19.6% | 17.8% | ||||||||||
Prime Vendor — Medline Brand Net Sales($M)1 | 1,719 | 1,707 | 1,605 | 1,607 | 1,448 | 1,476 | 1,453 | 1,493 | |||||
Prime Vendor — Medline Brand Growth (YoY)(%) | 18.7% | 15.7% | 10.5% | ||||||||||
Organic Net Sales Growth(%)4 | 10.5% | 11.5% | 10.1% | 14.4% | |||||||||
Organic Net Sales Growth ($M)($M) | 748 | 791 | 674 | 976 | |||||||||
Reported Net Sales Growth(%) | 10.4% | 11.6% | 10.7% | 14.8% | |||||||||
Foreign Exchange Impact on Net Sales ($M)($M) | -7 | 8 | 34 | 17 | |||||||||
Foreign Exchange Impact on Net Sales (%)(%) | -0.1% | 0.1% | 0.6% | 0.3% | |||||||||
Full-Year 2026 Guidance — Organic Sales Growth (Low)(%)3 | 10.0% | 9.0% | 8.5% | 8.0% | |||||||||
Full-Year 2026 Guidance — Organic Sales Growth (High)(%) | 10.5% | 10.0% | 9.5% | 9.0% | |||||||||
Full-Year 2026 Guidance — Adjusted EBITDA (Low)($M) | 3,300 | 3,300 | 3,500 | 3,500 | |||||||||
Full-Year 2026 Guidance — Adjusted EBITDA (High)($M) | 3,400 | 3,400 | 3,600 | 3,600 | |||||||||
Medline Brand Segment — Net Sales($M)1 | 3,637 | 3,540 | 3,465 | 3,723 | 3,411 | 3,322 | 3,264 | 3,329 | 3,123 | ||||
Medline Brand — Segment Adjusted EBITDA Margin(%) | 25.9% | 30.1% | 22.1% | 21.3% | 24.1% | 26.8% | 25.4% | 24.8% | |||||
Supply Chain Solutions Segment — Net Sales($M)1 | 4,219 | 4,145 | 3,887 | 4,064 | 3,704 | 3,564 | 3,380 | 3,455 | 3,265 | ||||
Supply Chain Solutions — Segment Adjusted EBITDA Margin(%) | 4.4% | 4.9% | 4.8% | 5.3% | 5.5% | 5.6% | 5.4% | 4.9% | |||||
Total Segment Adjusted EBITDA (Before Corporate)($M)1 | 1,127 | 1,271 | 952 | 1,010 | 1,026 | 1,091 | 1,012 | 992 | 1,007 | ||||
Corporate & Other Unallocated Adjusted EBITDA($M) | -167 | -211 | -176 | -205 | -167 | -156 | -144 | -182 | -127 | ||||
Consolidated Long-Lived Assets, Net($M)2 | 5,202 | 5,092 | 5,164 | 5,210 | 5,135 | 4,979 | |||||||
United States Long-Lived Assets, Net($M) | 4,364 | 4,277 | 4,359 | 4,433 | 4,393 | 4,329 | |||||||
International Long-Lived Assets, Net($M) | 838 | 815 | 805 | 777 | 742 | 650 | |||||||
Inventories — Finished Goods($M)2 | 4,036 | 3,870 | 3,972 | 4,021 | 3,780 | ||||||||
Inventories — Raw Materials & Work in Process($M) | 770 | 795 | 835 | 748 | 676 | ||||||||
Inventory Valuation & Obsolescence Reserves($M) | 60 | 56 | 56 | 44 | 35 | ||||||||
Unconditional Purchase Obligations — Total($M)6 | 710 | 753 | 805 | 849 | |||||||||
Payments Made Under Unconditional Purchase Obligations($M) | 43 | 52 | 42 | 56 | 137 | 44 | 49 | ||||||
Purchase Obligations Due in Next Fiscal Year($M) | 162 | 162 | 162 | 172 | |||||||||
Purchase Obligations Due in Year 2($M) | 169 | 169 | 169 | 162 | |||||||||
Purchase Obligations Due in Year 3($M) | 172 | 172 | 172 | 169 | |||||||||
Purchase Obligations Due in Year 4($M) | 115 | 115 | 115 | 172 | |||||||||
Purchase Obligations Due Thereafter($M) | 59 | 59 | 59 | ||||||||||
Consolidated Adjusted EBITDA($M)6 | 960 | 1,060 | 776 | 805 | 859 | 935 | 868 | 810 | |||||
Consolidated Adjusted EBITDA Margin(%) | 12.2% | 13.8% | 10.6% | 10.3% | 12.1% | 13.6% | 13.1% | 11.9% | |||||
Consolidated Gross Profit Margin(%) | 24.5% | 28.8% | 25.0% | 26.4% | 27.7% | 27.5% | |||||||
EBITDA Adjustment — Non-Cash LIFO & Inventory Step-Up($M) | 122 | 3 | 29 | 45 | 2 | 15 | 21 | ||||||
EBITDA Adjustment — Stock-Based Compensation($M) | 29 | 29 | 23 | 27 | 15 | 15 | 22 | ||||||
EBITDA Adjustment — Transaction, Integration & IPO Costs($M) | 30 | 29 | 35 | 23 | 12 | 11 | 12 | 9 | |||||
EBITDA Adjustment — Other Non-Core Charges($M) | 16 | 389 | 8 | 63 | 19 | 75 | 52 | 11 | |||||
Adjusted Net Income($M)2 | 577 | 666 | 433 | ||||||||||
Adjusted Diluted Earnings Per Share($) | 0.44 | 0.50 | 0.33 | ||||||||||
Adjusted Diluted Shares (Assuming Full Up-C Exchange)(M) | 1,319 | 1,340 | 1,318 | ||||||||||
Non-GAAP Free Cash Flow($M) | 884 | 604 | 316 | 91 | 535 | 87 | 584 | ||||||
Net Leverage Ratio (Net Debt / TTM Adjusted EBITDA)(×)6 | 2.50 | 2.90 | 3.10 | 3.10 | 4.90 | ||||||||
Net Debt($M) | 9,135 | 10,073 | 10,519 | 10,816 | 16,558 | ||||||||
Trailing-Twelve-Month Adjusted EBITDA($M) | 3,601 | 3,500 | 3,375 | 3,467 | 3,361 | ||||||||
Long-Term Debt Maturities — Next 12 Months / Year 1($M) | 28 | 28 | 76 | 76 | |||||||||
Long-Term Debt Maturities — Year 2($M) | 27 | 27 | 726 | 76 | |||||||||
Long-Term Debt Maturities — Year 3($M) | 8,027 | 8,027 | 8,535 | 726 | |||||||||
Long-Term Debt Maturities — Year 4($M) | 28 | 28 | 3,342 | 8,535 | |||||||||
Class A Common Stock Outstanding(M)1 | 879 | 877 | 846 | 812 | 0 | ||||||||
Class B Common Stock (Continuing Equity Owners' Medline Holdings Units)(M) | 437 | 437 | 468 | 502 | 0 | ||||||||
Tax Receivable Agreement (TRA) Liability — Total($M)3 | 4,415 | 4,404 | 4,021 | 3,542 | 0 | ||||||||
Tax Receivable Agreement Liability — Current($M) | 12 | 12 | 12 | ||||||||||
Tax Receivable Agreement Liability — Noncurrent($M) | 4,403 | 4,392 | 4,009 | 3,542 | |||||||||
TRA Liability Recognized from Unit Exchanges($M) | 11 | 383 | 479 | 3,542 | 0 | 0 | 0 | ||||||
Definite-Lived Customer Relationships Intangible, Net($M)9 | 7,892 | 8,036 | 8,183 | 8,328 | 8,892 | ||||||||
Indefinite-Lived Tradenames($M) | 3,830 | 3,830 | 3,830 | 3,830 | 3,830 | ||||||||
Definite-Lived Tradenames, Net($M) | 13 | 14 | 15 | 15 | 20 | ||||||||
Developed Technology Intangible, Net($M) | 1,642 | 1,658 | 1,689 | 1,720 | 1,817 | ||||||||
Intangible Asset Amortization Expense($M) | 176 | 177 | 176 | 176 | 177 | 176 | 175 | ||||||
Estimated Future Intangible Amortization — Next 12 Months / Year 1($M) | 705 | 704 | 704 | 704 | |||||||||
Estimated Future Intangible Amortization — Year 2($M) | 705 | 704 | 704 | 704 | |||||||||
Estimated Future Intangible Amortization — Year 3($M) | 704 | 702 | 702 | 704 | |||||||||
Estimated Future Intangible Amortization — Year 4($M) | 703 | 701 | 701 | 702 | |||||||||
Allowance for Credit Losses on Accounts Receivable($M) | 148 | 148 | 148 | 152 | 108 | ||||||||
U.S. Federal Contract Obligations to Medline — Total($M)3 | 271 | 261 | 220 | 235 | 251 | 135 | 147 | 46.3 | 129 | 122 | 87.7 | 32.3 | |
Department of Veterans Affairs (VA) Contract Obligations($M) | 251 | 245 | 213 | 225 | 233 | 105 | 126 | 35.7 | 117 | 108 | 72.8 | 23.3 | |
Department of Defense (DoD / Defense Health Agency) Obligations($M) | 0 | 0.10 | 0 | 0 | 0.10 | 0.20 | 0 | 0 | 0 | 0.20 | 0.10 | 0.20 | |
Department of Health & Human Services (HHS) Obligations($M) | 18.1 | 11.9 | 3.70 | 7.51 | 14.3 | 27.9 | 18.6 | 8.62 | 10.8 | 9.30 | 13.1 | 6.80 | |
FDA 510(k) Premarket Clearances — Medline1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 3 | 1 | 5 | 5 | |
U.S. Medical Device Industry — Total FDA 510(k) Clearances | 855 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
FDA Medical Device Recall Events — Medline1 | 95 | 272 | 121 | 56 | 17 | 65 | 51 | 134 | 191 | 21 | 88 | 19 | |
FDA Recall Enforcement Reports — Medline | 138 | 233 | 117 | 65 | 12 | 90 | 57 | 99 | 197 | 41 | 62 | 20 | |
FDA MAUDE Adverse Event Reports — Medline Total4 | 50,379 | 3,360 | 577 | 398 | 384 | 295 | 255 | 310 | 273 | 570 | 714 | 246 | |
MAUDE Device Malfunction Reports — Medline | 49,948 | 3,223 | 449 | 210 | 214 | 163 | 119 | 157 | 106 | 364 | 578 | 139 | |
MAUDE Patient Injury Reports — Medline | 184 | 130 | 124 | 185 | 166 | 131 | 129 | 151 | 160 | 199 | 131 | 105 | |
MAUDE Death Reports — Medline | 4 | 6 | 4 | 3 | 4 | 1 | 7 | 0 | 6 | 5 | 3 | 1 | |
U.S. Medical Device Industry — Total FDA MAUDE Reports | 1,189,467 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
U.S. PPI — Surgical Appliance & Supplies Manufacturing (Index)(×)5 | 269.30 | 263.80 | 253.80 | 251.40 | 249.60 | 249.50 | 248.70 | 245.40 | 245.10 | 243.70 | 240.10 | 238.50 | |
U.S. PPI — Surgical & Medical Instrument Manufacturing (Index)(×) | 163.40 | 162.90 | 161.70 | 159.60 | 157.80 | 156.90 | 157.10 | 155.20 | 154.40 | 154.10 | 153.60 | 151.00 | |
U.S. PPI — Electromedical Apparatus Manufacturing (Index)(×) | 92.80 | 92.10 | 92.00 | 91.60 | 90.70 | 90.30 | 90.10 | 89.50 | 89.30 | 88.40 | 88.30 | 87.80 | |
U.S. CPI — Medical Care Commodities (Index)(×) | 404.90 | 410.40 | 416.80 | 417.00 | 416.50 | 416.00 | 412.60 | 415.90 | 414.50 | 408.30 | 410.10 | ||
U.S. CPI — Medical Care Services (Index)(×) | 654.70 | 650.90 | 647.60 | 638.40 | 630.60 | 623.40 | 619.60 | 613.00 | 611.40 | 605.80 | 597.90 | ||
U.S. Census QSS — General Medical & Surgical Hospitals Revenue($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Consolidated Net Sales (GAAP)($M)9 | 7,856 | 7,685 | 7,352 | 7,787 | 7,115 | 6,886 | 6,644 | ||||||
Cost of Goods Sold($M) | 5,931 | 5,470 | 5,511 | 5,873 | 5,240 | 4,981 | 4,820 | ||||||
Gross Profit($M) | 1,925 | 2,215 | 1,841 | 1,914 | 1,875 | 1,905 | 1,824 | ||||||
Selling, General & Administrative Expenses($M) | 1,259 | 1,295 | 1,228 | 1,265 | 1,116 | 1,073 | 1,070 | ||||||
Total Operating Expenses($M) | 1,425 | 1,820 | 1,419 | 1,489 | 1,301 | 1,263 | 1,253 | ||||||
Operating Income($M) | 500 | 395 | 422 | 425 | 574 | 642 | 571 | ||||||
Interest Expense($M) | 165 | 168 | 165 | 200 | 248 | 253 | 244 | ||||||
Interest Income($M) | 47 | 49 | 29 | 34 | 35 | 30 | 34 | ||||||
Income Before Income Taxes($M) | 386 | 235 | 291 | 206 | 345 | 359 | 338 | ||||||
Income Tax Provision($M) | 68 | 96 | 52 | 26 | 23 | 26 | 16 | ||||||
Consolidated Net Income (GAAP)($M)4 | 318 | 139 | 239 | 193 | 318 | 329 | 319 | ||||||
Net Income Attributable to Noncontrolling Interests($M) | 123 | 79 | 110 | -2 | 0 | 0 | 0 | ||||||
Net Income Attributable to Medline Inc.($M) | 198 | 59 | 132 | ||||||||||
GAAP Diluted Earnings Per Share($) | 0.22 | 0.07 | 0.16 | ||||||||||
GAAP Weighted-Average Diluted Class A Shares(M) | 1,316 | 861 | 825 | ||||||||||
Total Assets($M)7 | 40,178 | 39,350 | 39,014 | 38,484 | 35,978 | ||||||||
Cash & Cash Equivalents($M) | 2,321 | 2,327 | 2,236 | 1,939 | 955 | 584 | 840 | 250 | 1,585 | ||||
Accounts Receivable, Net($M) | 3,794 | 3,661 | 3,674 | 3,533 | 3,219 | ||||||||
Inventories, Net($M) | 4,806 | 4,665 | 4,807 | 4,769 | 4,456 | ||||||||
Total Current Assets($M) | 12,653 | 11,742 | 11,180 | 10,679 | 8,272 | ||||||||
Property, Plant & Equipment, Net($M) | 4,728 | 4,697 | 4,758 | 4,778 | 4,595 | ||||||||
Goodwill($M) | 8,073 | 8,072 | 8,076 | 8,079 | 8,065 | 7,532 | |||||||
Definite & Indefinite-Lived Intangible Assets, Net($M) | 13,377 | 13,538 | 13,717 | 13,893 | 14,559 | ||||||||
Total Liabilities($M)5 | 20,792 | 20,273 | 19,665 | 19,198 | 19,454 | ||||||||
Accounts Payable($M) | 1,209 | 1,043 | 932 | 961 | 869 | ||||||||
Accrued Expenses & Other Current Liabilities($M) | 1,891 | 1,638 | 1,527 | 1,452 | 1,493 | ||||||||
Total Current Liabilities($M) | 3,129 | 2,710 | 2,536 | 2,490 | 2,440 | ||||||||
Current Portion of Long-Term Debt & Short-Term Borrowings($M) | 29 | 29 | 77 | 77 | 78 | ||||||||
Long-Term Debt, Less Current Portion($M) | 12,551 | 12,548 | 12,495 | 12,484 | 16,416 | ||||||||
Total Stockholders' Equity & Partners' Capital($M)2 | 19,386 | 19,077 | 19,349 | 19,286 | |||||||||
Medline Inc. Stockholders' Equity($M) | 11,801 | 11,572 | 11,272 | 10,737 | |||||||||
Noncontrolling Interests (Medline Holdings, LP)($M) | 7,585 | 7,505 | 8,077 | 8,549 | |||||||||
Net Cash Provided by Operating Activities($M)6 | 1,025 | 715 | 412 | 229 | 636 | 197 | 682 | ||||||
Capital Expenditures($M) | 141 | 111 | 96 | 138 | 101 | 110 | 98 | ||||||
Cash Paid for Acquisitions, Net of Cash Acquired($M) | 0 | 0 | 0 | 0 | 0 | 0 | -6 | ||||||
Depreciation & Amortization($M) | 259 | 256 | 254 | 261 | 253 | 250 | 247 | ||||||
Stock-Based Compensation (Cash Flow)($M) | 29 | 29 | 23 | 27 | 15 | 15 | 19 | ||||||
Net Cash Used in Investing Activities($M) | -980 | -461 | -96 | -138 | -101 | -143 | -92 | ||||||
Net Cash Used in Financing Activities($M) | -48 | -159 | -13 | 897 | -161 | -328 | -9 | ||||||
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Medline Inc. operates on a 52- or 53-week fiscal year ending near December 31 (Q1 2026 ended March 28, 2026; Q2 2026 ended June 27, 2026; Q3 2026 ended September 26, 2026).
- Medline completed its initial public offering on December 17, 2025 under an Up-C partnership structure holding Common Units in Medline Holdings, LP; pre-IPO historical figures reflect Medline Holdings, LP on a consistent consolidated GAAP basis.
- Standalone Q4 flow figures not separately printed in quarterly filings are derived strictly as full-year minus nine-month year-to-date figures from the corresponding SEC filings.
- U.S. GAAP consolidated financial statements do not include parent-only operating income statements (Medline Inc. is a holding company whose sole material asset is its equity interest in Medline Holdings, LP); consolidated-minus-standalone parent decomposition is not applicable.
Không hiện vì thiếu các kỳ gần đây (17)
- Manufacturing, Distribution Network & Supply Chain Operations › Tracy, CA Distribution Center Fire — Inventory Loss — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q2, FY2026Q3)
- Manufacturing, Distribution Network & Supply Chain Operations › Tracy, CA Distribution Center Fire — Fixed Asset Loss — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q2, FY2026Q3)
- Manufacturing, Distribution Network & Supply Chain Operations › Tracy, CA Distribution Center Fire — Insurance Proceeds Recognized — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q3)
- Manufacturing, Distribution Network & Supply Chain Operations › Medline ReNewal — Single-Use Medical Devices Reprocessed — Annual series ends prior to FY2025 (FY2019, FY2020, FY2021, FY2023); FY2024–FY2025 sustainability reports are not filed with the SEC or published in open archives
- Manufacturing, Distribution Network & Supply Chain Operations › Medline ReNewal — Hospital Landfill Waste Diverted (Pounds) — Annual series ends prior to FY2025 (FY2019, FY2020, FY2021, FY2022, FY2023); FY2024–FY2025 sustainability reports are not filed with the SEC or published in open archives
- Manufacturing, Distribution Network & Supply Chain Operations › Worldwide Employee Headcount (Point Count) — Annual series ends prior to FY2025 (FY2023); FY2024–FY2025 sustainability reports are not filed with the SEC or published in open archives
- Non-GAAP Profitability, Net Leverage & Up-C Structure › IEEPA Net Tariff Refund Benefit Recognized — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q3)
- Non-GAAP Profitability, Net Leverage & Up-C Structure › Share Repurchase Program Authorization — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2026Q3)
- Regulatory Surveillance, Federal Supply & Healthcare Benchmarks › FDA 510(k) Premarket Clearances — Medline › FDA Premarket Approvals (PMA) — Medline — Zero events across all periods (Medline manufactures Class I and Class II 510(k) devices rather than Class III PMA devices)
- Consolidated GAAP Financial Statements › Total Assets › Short-Term Investments — Fewer than 3 consecutive latest quarters through FY2026Q3 (FY2025Q4, FY2026Q2, FY2026Q3)
- Prime Vendor › Active Prime Vendor Relationships Count ('over 1,300 relationships' in Form 424B4 — disclosed only as a lower bound)
- Prime Vendor › Five-Year Average Prime Vendor Customer Retention Rate ('greater than 98%' in Form 424B4 — disclosed only as a lower bound)
- Supply Chain › MedTrans Private Fleet Truck Count in SEC Filings ('over 2,000' in FY2024 424B4; 'more than 2,100' in FY2025 10-K — lower bounds; FMCSA USDOT #987933 MCS-150 point census of 2,128 power units and 2,348 drivers is a single-period snapshot)
- Supply Chain › U.S. & Global Warehouse Square Footage ('over 26 million sq. ft.' U.S. and 'over 29 million sq. ft.' global — disclosed only as lower bounds in Form 424B4 and Form 10-K)
- Workforce › Worldwide & U.S. Employee Headcount in SEC Filings ('over 43,000' in FY2024 424B4; 'over 45,000 worldwide' and 'over 26,000 U.S.' in FY2025 10-K — disclosed only as lower bounds after FY2023)
- Innovation & Sourcing › Granted Patents ('more than 2,300'), Cumulative 510(k)s ('more than 450'), and Global Sourcing Partners ('more than 600' — disclosed only as lower bounds in Form 10-K)
- Commercial › 1H 2026 New Customer Signings ('more than $650 million' / 'over 65% of annual goal' in Q2 2026 release & call — lower bound and single semi-annual period)
Dữ liệu cập nhật 2026-11-07.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Prime Vendor & Commercial Engine
Segment Profitability, Product Lines & Care Settings
Manufacturing, Distribution Network & Supply Chain Operations
- Total Medical-Surgical SKU Catalog2 kỳ
- Global Distribution Facilities2 kỳ
- Medline Brand Manufacturing Facilities (Global)2 kỳ
- Owned & Leased Real Estate Sites — United States2 kỳ
- Inventories — Finished Goods ($M)5 kỳ
- Unconditional Purchase Obligations — Total ($M)4 kỳ
- Property, Plant & Equipment, Gross — Buildings & Improvements ($M)2 kỳ
- Total Lease Cost ($M)3 kỳ
Non-GAAP Profitability, Net Leverage & Up-C Structure
- Consolidated Adjusted EBITDA ($M)8 kỳ
- Adjusted Net Income ($M)3 kỳ
- Non-GAAP Free Cash Flow ($M)7 kỳ
- Net Leverage Ratio (Net Debt / TTM Adjusted EBITDA) (×)5 kỳ
- Class A Common Stock Outstanding (M)5 kỳ
- Tax Receivable Agreement (TRA) Liability — Total ($M)5 kỳ
- Definite-Lived Customer Relationships Intangible, Net ($M)5 kỳ
Regulatory Surveillance, Federal Supply & Healthcare Benchmarks
- U.S. Federal Contract Obligations to Medline — Total ($M)106 kỳ
- FDA 510(k) Premarket Clearances — Medline154 kỳ
- FDA Medical Device Recall Events — Medline154 kỳ
- FDA MAUDE Adverse Event Reports — Medline Total154 kỳ
- ClinicalTrials.gov — Cumulative Medline-Sponsored Studies8 kỳ
- U.S. PPI — Surgical Appliance & Supplies Manufacturing (Index) (×)105 kỳ
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Medline
- SEC Form 10-Q (FY2026Q3, filed 2026-11-04) ↗
- SEC Form 10-K (FY2025, filed 2026-02-25) ↗
- SEC Form 8-K Ex. 99.1 Q3 2026 Earnings Release (2026-11-04) ↗
- SEC Form 10-K FY2025 (filed 2026-03-04) ↗
- SEC Form 8-K Ex. 99.1 Q4 & FY2025 Earnings Release (2026-02-25) ↗
- U.S. Department of the Treasury — USAspending.gov Federal Award Obligations (Recipient: Medline Industries) ↗
- U.S. FDA Center for Devices and Radiological Health — 510(k) Premarket Notification Database (openFDA) ↗
- U.S. FDA Medical Device Recalls & Enforcement Reports Database (openFDA) ↗
- U.S. FDA MAUDE Adverse Event Reports Database (openFDA) ↗
- U.S. BLS Producer Price Index — Surgical Appliance & Supplies Manufacturing (FRED: PCU339113339113) ↗
- SEC Form 10-Q Q3 2026 (filed 2026-11-04) ↗
- SEC Form 424B4 Secondary Prospectus (filed 2026-05-26) ↗
See a number that looks wrong?